{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:22:35Z","timestamp":1789705355261,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Dry eye disease is a highly prevalent condition that causes tear film instability, ocular discomfort, and visual disturbance. Lacrimera eye drops are approved for the short-term treatment of dry eye disease. We aimed to evaluate the clinical outcome of patients with moderate-to-severe dry eye disease treated with Lacrimera up to 1\u00a0month during routine clinical practice.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We retrospectively collected data from 25 patients with dry eye disease from the start of Lacrimera treatment up to 1\u00a0month of follow-up period. We analyzed standard clinical parameters to follow the course of the patients\u2019 dry eye signs and symptoms.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Based on corneal staining data, we found that the percentage of patients with intact corneas raised from 12 to 64% after 1\u00a0month of Lacrimera treatment. During this period, we also observed an increase in both tear breakup time (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and Schirmer\u2019s score (<jats:italic>p<\/jats:italic> \u2009&lt;\u20090.001), with lower values indicating severer signs. Lacrimera eye drops were judged by 29% of the patients to be effective at relieving eye symptoms.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Lacrimera appears to be safe and effective in the treatment of dry eye disease, as assessed by corneal staining, tear breakup time, and Schirmer\u2019s analyses. Our data suggest that the regenerative effect of Lacrimera eye drops peaks at 2\u00a0weeks and is sustained for at least 1\u00a0month when administered for a longer period of time.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s10792-020-01324-5","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T20:02:51Z","timestamp":1583179371000},"page":"1547-1552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Management of moderate-to-severe dry eye disease using chitosan-N-acetylcysteine (Lacrimera\u00ae) eye drops: a retrospective case series"],"prefix":"10.1007","volume":"40","author":[{"given":"Johannes","family":"Nepp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Knoetzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Prinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-5048","authenticated-orcid":false,"given":"Sonja","family":"Hoeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Prinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"1324_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jtos.2017.05.005","volume":"15","author":"JD Nelson","year":"2017","unstructured":"Nelson JD, Craig JP, Akpek EK et al (2017) TFOS DEWS II introduction. Ocul Surf 15:269\u2013275. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.005","journal-title":"Ocul Surf"},{"key":"1324_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY et al (2017) TFOS DEWS II epidemiology report. Ocul Surf 15:334\u2013365. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.003","journal-title":"Ocul Surf"},{"key":"1324_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK et al (2017) TFOS DEWS II definition and classification report. Ocul Surf 15:276\u2013283","journal-title":"Ocul Surf"},{"key":"1324_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","volume":"5","author":"DEWS","year":"2007","unstructured":"DEWS (2007) The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007). Ocul Surf 5:75\u201392","journal-title":"Ocul Surf"},{"key":"1324_CR5","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1185\/030079906X132640","volume":"22","author":"PA Asbell","year":"2006","unstructured":"Asbell PA (2006) Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion. Curr Med Res Opin 22:2149\u20132157. https:\/\/doi.org\/10.1185\/030079906X132640","journal-title":"Curr Med Res Opin"},{"key":"1324_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5192924","author":"C Fischak","year":"2017","unstructured":"Fischak C, Klaus R, Werkmeister RM et al (2017) Effect of topically administered chitosan-N-acetylcysteine on corneal wound healing in a rabbit model. J Ophthalmol. https:\/\/doi.org\/10.1155\/2017\/5192924","journal-title":"J Ophthalmol"},{"key":"1324_CR7","unstructured":"Dangl D, Hornof M, Hoffer M, et al (2009) In vivo evaluation of ocular residence time of 124I-labelled thiolated chitosan in rabbits using MicroPET technology. In: Investigative ophthalmology and visual science. [Association for Research in Vision and Ophthalmology, etc.], pp 3689\u20133689"},{"key":"1324_CR8","first-page":"411","volume":"4","author":"D Elieh-Ali-Komi","year":"2016","unstructured":"Elieh-Ali-Komi D, Hamblin MR (2016) Chitin and chitosan: production and application of versatile biomedical nanomaterials. Int J Adv Res 4:411\u2013427","journal-title":"Int J Adv Res"},{"key":"1324_CR9","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.3390\/md13085156","volume":"13","author":"RCF Cheung","year":"2015","unstructured":"Cheung RCF, Ng TB, Wong JH, Chan WY (2015) Marine drugs chitosan: an update on potential biomedical and pharmaceutical applications. Mar Drugs 13:5156\u20135186. https:\/\/doi.org\/10.3390\/md13085156","journal-title":"Mar Drugs"},{"key":"1324_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijpharm.2007.06.040","volume":"347","author":"T Schmitz","year":"2008","unstructured":"Schmitz T, Grabovac V, Palmberger TF et al (2008) Synthesis and characterization of a chitosan-N-acetyl cysteine conjugate. Int J Pharm 347:79\u201385. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.06.040","journal-title":"Int J Pharm"},{"key":"1324_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ijbiomac.2015.02.041","volume":"76","author":"F Felice","year":"2015","unstructured":"Felice F, Zambito Y, Belardinelli E et al (2015) Effect of different chitosan derivatives on in vitro scratch wound assay: a comparative study. Int J Biol Macromol 76:236\u2013241. https:\/\/doi.org\/10.1016\/j.ijbiomac.2015.02.041","journal-title":"Int J Biol Macromol"},{"key":"1324_CR12","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1021\/bm101192b","volume":"12","author":"H Zhang","year":"2011","unstructured":"Zhang H, Qadeer A, Chen W (2011) In situ gelable interpenetrating double network hydrogel formulated from binary components: thiolated chitosan and oxidized dextran. Biomacromol 12:1428\u20131437. https:\/\/doi.org\/10.1021\/bm101192b","journal-title":"Biomacromol"},{"key":"1324_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1089\/jop.2016.0123","volume":"33","author":"D Schmidl","year":"2017","unstructured":"Schmidl D, Kaya S, Unterhuber A et al (2017) A Controlled Randomized double-blind study to evaluate the safety and efficacy of chitosan-N-acetylcysteine for the treatment of dry eye syndrome. J Ocul Pharmacol Ther 33:375\u2013382. https:\/\/doi.org\/10.1089\/jop.2016.0123","journal-title":"J Ocul Pharmacol Ther"},{"key":"1324_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10792-018-0843-0","volume":"39","author":"M Messina","year":"2018","unstructured":"Messina M, Dua HS (2018) Early results on the use of chitosan-N-acetylcysteine (Lacrimera\u00ae) in the management of dry eye disease of varied etiology. Int Ophthalmol 39:693\u2013696","journal-title":"Int Ophthalmol"},{"key":"1324_CR15","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.ajo.2014.02.012","volume":"157","author":"YS Chun","year":"2014","unstructured":"Chun YS, Park IK (2014) Reliability of 4 clinical grading systems for corneal staining. Am J Ophthalmol 157:1097\u20131102. https:\/\/doi.org\/10.1016\/j.ajo.2014.02.012","journal-title":"Am J Ophthalmol"},{"key":"1324_CR16","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8412","author":"M Kaido","year":"2011","unstructured":"Kaido M, Matsumoto Y, Shigeno Y et al (2011) Corneal fluorescein staining correlates with visual function in dry eye patients. Investig Ophthalmol Vis Sci. https:\/\/doi.org\/10.1167\/iovs.11-8412","journal-title":"Investig Ophthalmol Vis Sci"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01324-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-020-01324-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01324-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:07:18Z","timestamp":1614643638000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-020-01324-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1007\/s10792-020-01324-5","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]},"assertion":[{"value":"17 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}